Merck KGaA : Failure of evobrutinib
>Phase III failed - The company announced that its phase III study for evobrutinib has not meet its primary endpoint of reducing the annualised relapse rates (ARR) in multiple sclerosis (MS) compared to oral teriflunomide. While the ARR of evobrutinib showed an ongoing unchanged level in phase III compared to previous phases, teriflunomide showed better efficacy than in other phase III studies. Consequently, we believe that the design of the phase III study had some p...Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.